A Phase 2, Single-Arm, Open-label, Study of RRx-001 in Second Line Treatment of Advanced Cholangiocarcinoma Prior to Readministration of First-Line Therapy

Trial Profile

A Phase 2, Single-Arm, Open-label, Study of RRx-001 in Second Line Treatment of Advanced Cholangiocarcinoma Prior to Readministration of First-Line Therapy

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 08 Jun 2018

At a glance

  • Drugs RRx 001 (Primary) ; Cisplatin; Gemcitabine
  • Indications Cholangiocarcinoma
  • Focus Therapeutic Use
  • Acronyms EPIC
  • Sponsors EpicentRx
  • Most Recent Events

    • 04 Jun 2018 Planned End Date changed from 1 Aug 2017 to 1 Dec 2018.
    • 04 Jun 2018 Planned primary completion date changed from 1 Aug 2017 to 1 Jun 2018.
    • 02 Jul 2017 Planned End Date changed from 1 May 2018 to 1 Aug 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top